DE102006045252B4 - Protein-free medium for the cultivation of Borrelia and its use - Google Patents
Protein-free medium for the cultivation of Borrelia and its use Download PDFInfo
- Publication number
- DE102006045252B4 DE102006045252B4 DE200610045252 DE102006045252A DE102006045252B4 DE 102006045252 B4 DE102006045252 B4 DE 102006045252B4 DE 200610045252 DE200610045252 DE 200610045252 DE 102006045252 A DE102006045252 A DE 102006045252A DE 102006045252 B4 DE102006045252 B4 DE 102006045252B4
- Authority
- DE
- Germany
- Prior art keywords
- acid
- chemically defined
- zinc
- bacteria
- culture media
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000589968 Borrelia Species 0.000 title claims abstract description 36
- 208000016604 Lyme disease Diseases 0.000 title claims abstract description 36
- 239000001963 growth medium Substances 0.000 claims abstract description 22
- 241000894006 Bacteria Species 0.000 claims abstract description 15
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 14
- 229930195729 fatty acid Natural products 0.000 claims abstract description 14
- 239000000194 fatty acid Substances 0.000 claims abstract description 14
- -1 fatty acid ester Chemical class 0.000 claims abstract description 10
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 6
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 235000005074 zinc chloride Nutrition 0.000 claims description 3
- 239000011592 zinc chloride Substances 0.000 claims description 3
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 4
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 4
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 claims 4
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 claims 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 2
- FPAQLJHSZVFKES-UHFFFAOYSA-N 5-Eicosenoic acid Natural products CCCCCCCCCCCCCCC=CCCCC(O)=O FPAQLJHSZVFKES-UHFFFAOYSA-N 0.000 claims 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 2
- 235000021357 Behenic acid Nutrition 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 2
- 239000005642 Oleic acid Substances 0.000 claims 2
- 235000021314 Palmitic acid Nutrition 0.000 claims 2
- 235000021319 Palmitoleic acid Nutrition 0.000 claims 2
- 235000021355 Stearic acid Nutrition 0.000 claims 2
- 150000001298 alcohols Chemical class 0.000 claims 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 2
- 229940114079 arachidonic acid Drugs 0.000 claims 2
- 235000021342 arachidonic acid Nutrition 0.000 claims 2
- 229940116226 behenic acid Drugs 0.000 claims 2
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 claims 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 2
- 229960004488 linolenic acid Drugs 0.000 claims 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 2
- 235000021313 oleic acid Nutrition 0.000 claims 2
- 239000008117 stearic acid Substances 0.000 claims 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000032050 esterification Effects 0.000 claims 1
- 238000005886 esterification reaction Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims 1
- DJWUNCQRNNEAKC-UHFFFAOYSA-L zinc acetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O DJWUNCQRNNEAKC-UHFFFAOYSA-L 0.000 claims 1
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 claims 1
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 claims 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims 1
- 238000012258 culturing Methods 0.000 abstract description 5
- 235000018102 proteins Nutrition 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 101710105711 Outer surface protein C Proteins 0.000 description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000011534 incubation Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- OLXZPDWKRNYJJZ-UHFFFAOYSA-N 5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(CO)O1 OLXZPDWKRNYJJZ-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 4
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 4
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 4
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 description 2
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 2
- YKBGVTZYEHREMT-UHFFFAOYSA-N 2'-deoxyguanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 description 2
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 2
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- LUCHPKXVUGJYGU-XLPZGREQSA-N 5-methyl-2'-deoxycytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LUCHPKXVUGJYGU-XLPZGREQSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical class [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 239000004158 L-cystine Substances 0.000 description 2
- 235000019393 L-cystine Nutrition 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 229930182844 L-isoleucine Natural products 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 229930195722 L-methionine Natural products 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- HDVCHBLHEICPPP-UHFFFAOYSA-N O=P(=O)C1=CC=NC(P(=O)=O)=C1P(=O)=O Chemical class O=P(=O)C1=CC=NC(P(=O)=O)=C1P(=O)=O HDVCHBLHEICPPP-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- RCMJWNHTNMOEEV-NJXJZFGESA-L disodium (2S)-2-amino-3-(4-hydroxyphenyl)propanoate dihydrate Chemical compound O.O.[Na+].[Na+].N[C@@H](Cc1ccc(O)cc1)C([O-])=O.N[C@@H](Cc1ccc(O)cc1)C([O-])=O RCMJWNHTNMOEEV-NJXJZFGESA-L 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- LJPYJRMMPVFEKR-UHFFFAOYSA-N prop-2-ynylurea Chemical compound NC(=O)NCC#C LJPYJRMMPVFEKR-UHFFFAOYSA-N 0.000 description 2
- FCHXJFJNDJXENQ-UHFFFAOYSA-N pyridoxal hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(C=O)=C1O FCHXJFJNDJXENQ-UHFFFAOYSA-N 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 2
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 2
- ICQRTPLATMRWJI-JLWXJWIASA-M sodium;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoate;hydrate Chemical compound O.[Na+].O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C([O-])=O ICQRTPLATMRWJI-JLWXJWIASA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 229960000344 thiamine hydrochloride Drugs 0.000 description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 2
- 239000011747 thiamine hydrochloride Substances 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- IFDFNYURGGDNCU-UHFFFAOYSA-N (3-bromo-4-chloro-1H-indol-2-yl) dihydrogen phosphate Chemical compound C1=CC(Cl)=C2C(Br)=C(OP(O)(=O)O)NC2=C1 IFDFNYURGGDNCU-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241001148604 Borreliella afzelii Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241001148605 Borreliella garinii Species 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- UJASNKJSHULBIQ-UHFFFAOYSA-L disodium 3-carboxy-3-hydroxypentanedioate dihydrate Chemical compound O.O.[Na+].[Na+].OC(=O)CC(O)(C([O-])=O)CC([O-])=O UJASNKJSHULBIQ-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 208000007865 relapsing fever Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Verfahren zur Kultivierung von Bakterien des Genus Borrelia, dadurch gekennzeichnet, dass die Bakterien mit einem Protein-freien Kulturmedium in Kontakt gebracht werden, das mindestens eine chemisch definierte Fettsäure oder mindestens einen chemisch definierten Fettsäureester sowie mindestens eine chemisch definierte Zink(II)-Verbindung enthält und das Wachstum der Bakterien unterstützt.Method for culturing bacteria of the Borrelia genus, characterized in that the bacteria are brought into contact with a protein-free culture medium which contains at least one chemically defined fatty acid or at least one chemically defined fatty acid ester and at least one chemically defined zinc (II) compound and supports the growth of bacteria.
Description
Die vorliegende Erfindung betrifft Protein-freie Kulturmedien, die zur Kultivierung, insbesondere Vermehrung, von Bakterien des Genus Borrelia geeignet sind, und deren Verwendung zur Kultivierung, insbesondere Vermehrung, von Bakterien des Genus Borrelia. Des weiteren betrifft die vorliegende Erfindung Kulturmedien auf Basis der beschriebenen Kulturmedien, die durch Supplementierung mit definierten Komponenten zu erhalten sind, und deren Verwendung zur Kultivierung, insbesondere Vermehrung, von Bakterien des Genus Borrelia.The present invention relates to protein-free culture media which are suitable for culturing, in particular propagation, of bacteria of the genus Borrelia, and their use for culturing, in particular propagation, of bacteria of the genus Borrelia. Furthermore, the present invention relates to culture media based on the described culture media, which can be obtained by supplementation with defined components, and their use for culturing, in particular propagation, of bacteria of the genus Borrelia.
Stand der Technik:State of the art:
Bakterien des Genus Borrelia sind als Erreger mehrerer humaner Erkankungen, insbesondere als Erreger der Lyme-Borreliose und des Rückfallfiebers, beschrieben. Für ihren Nachweis sowie für die Erforschung z. B. des Infektionsmechanismus und die Entwicklung von Impfstoffen werden sie regelmäßig in vitro vermehrt.Borrelia bacteria are described as causing several human diseases, in particular as Lyme disease and relapsing fever. For their proof as well as for the research z. As the infection mechanism and the development of vaccines, they are regularly propagated in vitro.
Für die in vitro-Kultivierung von Borrelien werden im Wesentlichen komplexe Kulturmedien verwendet, die natürliche, chemisch nicht definierbare Bestandteile wie proteinhaltige Serumfraktionen von Mammalia und komplexe Proteingemische, z. B. proteolytisch behandelte Muskelextrakte, Hefeextrakte oder Gelatine enthalten. Als ein Ausführungsbeispiel sei die kommerziell erhältliche Variante mit der Bezeichnung Complete BSK-H angeführt (Produktinformation B8291, Sigma-Aldrich). Ähnliche Zusammensetzungen sind mit den Bezeichnungen MKP und BSK II in der Literatur beschrieben (Ruzic-Sabljic et al. 2004, Int. J Med. Microbiol.).For the in vitro cultivation of Borrelia, essentially complex culture media are used which contain natural, chemically undefinable components such as proteinaceous mammalian serum fractions and complex protein mixtures, e.g. As proteolytically treated muscle extracts, yeast extracts or gelatin. As an embodiment, the commercially available variant with the name Complete BSK-H is mentioned (product information B8291, Sigma-Aldrich). Similar compositions are described in the literature as MKP and BSK II (Ruzic-Sabljic et al., 2004, Int J Med. Microbiol.).
Nachteiligerweise unterliegen die chemisch nicht definierbaren Bestandteile dieser Medien starken Schwankungen ihrer Zusammensetzungen von Charge zu Charge, bergen das Risiko der Verunreinigung mit Viren oder Mycoplasmen, sind kostenintensiv in der Herstellung und erschweren das Studium von Sekretionsprozessen und Einflüssen chemisch definierter Komponenten auf die kultivierten Borrelien sowie die gentechnische Veränderung der Borrelien.Disadvantageously, the chemically undefinable components of these media are subject to large variations in their compositions from batch to batch, carry the risk of contamination with viruses or mycoplasma, are expensive to manufacture and complicate the study of secretion processes and effects of chemically defined components on the cultured Borrelia and the genetic modification of borrelia.
Dementsprechend zeigen in vitro-kultivierte Borrelien üblicherweise in Abhängigkeit der jeweils verwendeten Kulturmedien bzw. in Abhängigkeit einzelner Komponenten der jeweils verwendeten Kulturmedien starke Schwankungen ihrer Wachstumsraten und ihrer Genexpression. Insbesondere sind hiervon Gene betroffen, die in vivo in Abhängkeit des jeweiligen Wirtsorganismus exprimiert werden (Pollack et al. 1993, J. Clin. Microbiol.; Yang et al. 2001, Infect. Immun.). Dadurch lassen sich insbesondere Ergebnisse unterschiedlicher Laboratorien, die Borrelien kultivieren, schlecht miteinander vergleichen.Accordingly, in vitro cultured Borrelia usually show, depending on the particular culture media used or depending on individual components of the culture media used in each case strong fluctuations in their growth rates and their gene expression. In particular, this affects genes which are expressed in vivo as a function of the respective host organism (Pollack et al., 1993, J. Clin. Microbiol, Yang et al., 2001, Infect. Immun.). This makes it difficult to compare the results of different laboratories cultivating Borrelia in particular.
Die Entwicklung eines zuverlässigen, chemisch definierten Kulturmediums basierend auf besser standardisierbaren Bestandteilen ist daher erforderlich, um die Untersuchung des Einflusses chemisch definierter Komponenten auf Borrelien und deren gentechnische Veränderung zu erleichtern bzw. zu ermöglichen und Ergebnisse verschiedener Laboratorien zu standardisieren.The development of a reliable, chemically defined culture medium based on more standardized components is therefore necessary to facilitate the investigation of the influence of chemically defined components on Borrelia and their genetic modification and to standardize the results of different laboratories.
Es wurde bereits früher versucht, Borrelien in einem chemisch definierten, Serum-freien Kulturmedium zu kultivieren (Alban et al. 2000, Microbiology). Dabei zeigte sich, dass Borrelien mit dem beschriebenen Kulturmedium RPMI 1640 nicht vermehrbar sind, sondern im Gegenteil, abhängig von der Kultivierungsdauer, absterben. Zwei Wochen nach Beimpfung des Mediums mit lebenden Borrelien waren bereits keine lebenden Borrelien mehr nachweisbar. Dieses Medium ist dementsprechend nicht geeignet zur Lösung der beschriebenen Probleme.It has previously been attempted to culture Borrelia in a chemically defined, serum-free culture medium (Alban et al 2000, Microbiology). It was found that Borrelia with the described culture medium RPMI 1640 are not reproducible, but on the contrary, depending on the cultivation period, die off. Two weeks after inoculation of the medium with living Borrelia, no living Borrelia were detectable. Accordingly, this medium is not suitable for solving the problems described.
Beschreibung der Erfindung:Description of the invention:
Überraschenderweise wurde nun festgestellt, dass sich die beschriebenen Probleme durch den Gegenstand der Ansprüche 1 bis 15 lösen lassen, insbesondere durch Kultivierung, insbesondere Vermehrung, der Borrelien in Serum-freien, niedrig-Protein-haltigen oder Protein-freien Medien, sodass sie zu einem beliebigen Zeitpunkt nach Beimpfung mehrheitlich lebendig bzw. lebens- und vermehrungsfähig sind. Voraussetzung ist das Entfernen verbrauchten und Zuführen frischen Mediums in geeigneten Intervallen z. B. durch Zentrifugation und Resuspendierung. Dem Fachmann sind solche Notwendigkeiten bei der Kultivierung von Mikroorganismen bekannt.Surprisingly, it has now been found that the problems described can be solved by the subject matter of claims 1 to 15, in particular by culturing, in particular propagation, the Borrelia in serum-free, low-protein or protein-free media, so that they to a Any time after inoculation are mostly alive or able to live and reproduce. Prerequisite is the removal of spent and feeding fresh medium at appropriate intervals z. B. by centrifugation and resuspension. Those skilled in the art are aware of such needs in the cultivation of microorganisms.
Die vorliegende Erfindung ermöglicht erstmalig die Kultivierung, insbesondere Vermehrung, von Borrelien in Abwesenheit von Serum, insbesondere in Abwesenheit von Proteinen.The present invention makes it possible for the first time to cultivate, in particular multiply, borrelia in the absence of serum, in particular in the absence of proteins.
Es wurde gezeigt, dass Borrelien in Medien entsprechend der Zusammensetzungen gemäß Tabelle 1 oder Tabelle 2, die optional mit unterschiedlichen chemisch definierbaren und chemisch nicht definierbaren Komponenten, etwa Phosphomycin, Rifampicin, Amphotericin B, bovines Serumalbumin (BSA) oder Kaninchenserum, supplementiert waren, kultivierbar, insbesondere vermehrbar, waren. Dabei entsprachen die Wachstumsraten in etwa denen von Borrelien, die in Complete BSK-H kultiviert wurden. Borrelia were shown to be culturable in media corresponding to the compositions shown in Table 1 or Table 2 which were optionally supplemented with various chemically definable and chemically undefinable components such as phosphomycin, rifampicin, amphotericin B, bovine serum albumin (BSA) or rabbit serum , in particular reproducible, were. The growth rates were similar to those of Borrelia, which were cultured in Complete BSK-H.
Darüber hinaus wurde gezeigt, dass das üblichweise verwendete Kaninchenserum und die sonstigen chemisch nicht definierbaren Proteingemische (Muskelextrakt, Hefeextrakt, Gelatine) durch ein Lipidgemisch (L5146, Sigma-Aldrich), das neben dem auch in Complete BSK-H definiert zugegebenen Cholesterin im Wesentlichen Fettsäuren und Fettsäureester enthält, substituiert werden können.In addition, it has been shown that the commonly used rabbit serum and the other chemically non-definable protein mixtures (muscle extract, yeast extract, gelatin) by a lipid mixture (L5146, Sigma-Aldrich), in addition to the cholesterol also defined in Complete BSK-H essentially fatty acids and fatty acid esters can be substituted.
Des Weiteren wurde gezeigt, dass das üblichweise verwendete BSA durch Zink(II)-Verbindungen, insbesondere durch Zink(II)chlorid, substituiert werden kann.Furthermore, it has been shown that the commonly used BSA can be substituted by zinc (II) compounds, in particular by zinc (II) chloride.
Der Nachweis der Identität der kultivierten Organismen wurde durch Westernblot-Analyse mit einem für Outer Surface Protein C (OspC) spezifischen Antiserum aus Kaninchen geführt. Dabei zeigte sich, dass die Menge an exprimiertem OspC jeweils in etwa proportional zu der Menge der kultivierten Borrelien war, woraus zu schließen ist, dass es sich um Borrelien handelte.Evidence of the identity of the cultured organisms was obtained by Western blot analysis with rabbit rabbit antiserum specific for Outer Surface Protein C (OspC). It was found that the amount of OspC expressed was in each case approximately proportional to the amount of cultured Borrelia, which led to the conclusion that they were Borrelia.
Nach Beschreibung der genauen Zusammensetzung von Serumfreien, niedrig-Protein-haltigen oder Protein-freien Medien, die zur Kultivierung, insbesondere Vermehrung, von Borrelien geeignet sind, ist es für den durchschnittlich qualifizierten Fachmann offensichtlich, dass ähnliche Ergebnisse durch Modifizierung oder Veränderung der Erfindung, insbesondere durch Modifizierung oder Veränderung der Zusammensetzung der verwendeten Medien, erzielbar sind, ohne den Betreff der Erfindung oder eines ihrer, Ausführungsbeispiele zu beeinträchtigen. Solche Modifizierungen oder Veränderung sind dementsprechend ebenfalls Gegenstand der Ansprüche 1 bis 15.Having described the exact composition of serum-free, low-protein or protein-free media suitable for cultivating, in particular propagating, Borrelia, it will be apparent to those of ordinary skill in the art that similar results may be obtained by modifying or altering the invention. in particular by modifying or altering the composition of the media used, without affecting the subject of the invention or any of its embodiments. Accordingly, such modifications or alterations are also subject matter of claims 1 to 15.
BeispieleExamples
Beispiel 1: Kultivierung von Borrelien in Serum-freiem MediumExample 1: Cultivation of Borrelia in serum-free medium
Jeweils 30 ml eines steril-filtrierten Mediums der Zusammensetzung entsprechend Tabelle 1 werden mit jeweils 2 × 106 Zellen von Borrelia burgdorferi (Stamm B31), Borrelia afzelii (Stamm VS461) oder Borrelia garinii (Stamm 20047) unter der sterilen Sicherheitswerkbank inokkuliert und bei 37°C in einem geschlossenen Gefäß inkubiert. Während der Inkubation werden die Zellsuspensionen im Abstand von jeweils zwölf Stunden durch leichtes Schütteln verwirbelt. Parallel dazu wird die gleich Anzahl der jeweiligen Organismen in jeweils 30 ml Complete BSK-H (B8291, Sigma-Aldrich) inokkuliert und identisch inkubiert. Zu unterschiedlichen Zeitpunkten werden Proben entnommen und die Zellen mit Hilfe einer geeigneten Zählkammer im Dunkelfeldmikroskop ausgezählt.In each case 30 ml of a sterile-filtered medium of the composition according to Table 1 are inoculated with 2 × 10 6 cells of Borrelia burgdorferi (strain B31), Borrelia afzelii (strain VS461) or Borrelia garinii (strain 20047) under the sterile safety cabinet and 37 ° C incubated in a closed vessel. During the incubation, the cell suspensions are vortexed at intervals of twelve hours each by gentle shaking. In parallel, the same number of respective organisms in each of 30 ml Complete BSK-H (B8291, Sigma-Aldrich) is inoculated and incubated identically. Samples are taken at different times and the cells counted using a suitable counting chamber in the dark field microscope.
Darüber hinaus werden entnommene Zellen in PBS (50 mN Natriumhydrogenphosphat pH 7,4; 150 mM NaCl) resuspendiert und die Menge der enthaltenen Proteine durch eine Proteinbestimmung (DC Assay, Biorad) analysiert. Anschließend werden Proteine der verschiedenen Borrelienproben durch SDS-PAGE aufgetrennt und auf eine Nitrocellulose-Membran transfertiert, erst mit Ponceau S gefärbt und dann mit einem Antiserum gegen OspC aus Kaninchen inkubiert.In addition, extracted cells are resuspended in PBS (50 mM sodium hydrogen phosphate pH 7.4, 150 mM NaCl) and the amount of proteins contained analyzed by protein determination (DC assay, Biorad). Subsequently, proteins of the various borrelia samples are separated by SDS-PAGE and transfected onto a nitrocellulose membrane, stained first with Ponceau S and then incubated with an antiserum against rabbit OspC.
Für die spezifische immunologische Detektion mit Antikörpern wird die Membran, ggf. in Streifen geschnitten, zuerst 15 Minuten mit Universalpuffer (EUROIMMUN) mit 3% (w/v) Milchpulver blockiert. Anschließend wird 3 Stunden mit einem humanen Serum (1:200 in Universalpuffer mit 3% (w/v) Milchpulver) inkubiert. Dann wird dreimal jeweils 5 Minuten mit Universalpuffer gewaschen. In einem zweiten Inkubationsschritt reagieren die im positiven Fall an die Proteine gebundenen Antikörper mit einer Konjugat-Lösung (EUROIMMUN, 1:10 in Universalpuffer verdünnt), die alkalische Phosphatase-markierte Anti-Kaninchen-IgG-Antikörper enthält.For specific immunological detection with antibodies, the membrane, if necessary cut into strips, is first blocked for 15 minutes with Universal buffer (EUROIMMUN) with 3% (w / v) milk powder. Subsequently, it is incubated for 3 hours with a human serum (1: 200 in universal buffer with 3% (w / v) milk powder). Then it is washed three times for 5 minutes each with universal buffer. In a second incubation step, the antibodies bound to the proteins in the positive case react with a conjugate solution (EUROIMMUN diluted 1:10 in universal buffer) containing alkaline phosphatase-labeled anti-rabbit IgG antibodies.
Anschließend wird wie nach der Seruminkubation gewaschen. In einem dritten Inkubationsschritt werden dann die gebundenen Antikörper mit einer NBT/BCIP-Substrat-Lösung (4-Nitrobluetetrazoliumchlorid/Chlorobromoindolylphosphate, EUROIMMUN) nachgewiesen. Tabelle 1
Ergebnisse:Results:
Bei allen Kulturen, sowohl in dem Medium der Zusammensetzung gemäß Tabelle 1 als auch in Complete BSK-H, zeigt sich nach vier bis zehn Tagen eine Verfärbung des Kulturmedium von rot nach gelb. Der Farbwechsel zeigt jeweils eine Ansäuerung des Mediums durch den Stoffwechsel der enthaltenen Organismen an. Gleichzeitig wird eine Zunahme der Trübung der Suspension durch Zunahme der Anzahl der Organismen beobachtet.In all cultures, both in the medium of the composition according to Table 1 and in Complete BSK-H, a discoloration of the culture medium turns from red to yellow after four to ten days. The color change indicates in each case an acidification of the medium by the metabolism of the contained organisms. At the same time, an increase in the turbidity of the suspension is observed by an increase in the number of organisms.
Die Anzahl der Organismen in allen Kulturen zeigt jeweils einen sigmoidalen Zusammenhang zur Kulturdauer, typisch für sich durch Zellteilung vermehrende Organismen. Die Menge der Organismen bei Erreichen der Plateauphase beläuft sich dabei auf 108 bis 109 Zellen in einer 30 ml Kultur und ist in etwa proportional zur Gesamtproteinmenge der geernteten Zellen (4–6 mg).The number of organisms in all cultures each show a sigmoidal relationship to culture duration, typical of cell division-propagating organisms. The amount of organisms upon reaching the plateau phase amounts to 10 8 to 10 9 cells in a 30 ml culture and is approximately proportional to the total protein amount of the harvested cells (4-6 mg).
Bei auf Proteingehalt normierter Analyse der verschiedenen Proben im Westernblot, verbunden mit der Inkubation mit einem Antiserum gegen OspC zeigt sich jeweils eine Anfärbung eines Proteins entsprechend 25 kDa, der berechneten Masse des OspC. Die in etwa immer gleichstarke Färbung weist auf ein in etwa zur Proteinmenge konstantes Verhältnis des OspC hin.When normalized for protein analysis of the various samples in Western blot, combined with the incubation with an antiserum against OspC shows each a staining of a protein corresponding to 25 kDa, the calculated mass of OspC. The color, which is approximately the same in each case, indicates a ratio of the OspC which is approximately constant with respect to the protein amount.
Beispiel 2: Kultivierung von Borrelien in Protein-freiem Medium Example 2: Cultivation of Borrelia in protein-free medium
Die Kultivierung der drei Borrelien-Stämme erfolgt gemäß Beispiel 1. An Stelle des Mediums der Zusammensetzung gemäß Tabelle 1 wird jedoch ein Medium der Zusammensetzung gemäß Tabelle 2 verwendet.The cultivation of the three Borrelia strains is carried out according to Example 1. Instead of the medium of the composition according to Table 1, however, a medium of the composition according to Table 2 is used.
Der spezifische Nachweis der Borrelien erfolgt durch Westernblot gemäß Beispiel 1. Tabelle 2
Ergebnisse:Results:
Die Ergebnisse entsprechen im Wesentlichen Beispiel 1. Zusätzlich zeigt die Beobachtung der Bakterien im Dunkelfeldmikroskop, dass die in dem Medium der Zusammensetzung gemäß Tabelle 2 kultivierten Borrelien wesentlich kleiner als bei Kultivierung in Complete BSK-H oder Medium der Zusammensetzung gemäß Tabelle 1 sind. Darüber hinaus ist die Zellzahl pro 30 ml Kultur etwa um den Faktor fünf bis zehn erhöht, während die Proteinmenge pro 30 ml Kultur in etwa identisch ist.The results essentially correspond to Example 1. In addition, observation of the bacteria in the dark field microscope shows that the borrelia cultured in the medium of the composition according to Table 2 are substantially smaller than when cultivated in Complete BSK-H or medium of the composition according to Table 1. In addition, the cell count per 30 ml of culture is increased by a factor of about five to ten, while the amount of protein per 30 ml of culture is approximately identical.
Beispiel 3: Passage der Borrelien in unterschiedlichen MedienExample 3: Passage of borrelia in different media
Die Kultivierung der drei Borrelien-Stämme erfolgt gemäß Beispiel 1 oder 2. Kurz vor Erreichen der Plateauphase wird jeweils ein 200 μl Aliquot der jeweiligen Kultur unter der Sicherheitswerkbank entnommen und in ein neues Gefäß mit frischem Medium transferiert. Der Prozess wird über fünf Passagen (ca. vier bis sieben Wochen) weitergeführt.The cultivation of the three Borrelia strains is carried out according to Example 1 or 2. Shortly before reaching the plateau phase, a 200 ul aliquot of each culture is removed under the safety cabinet and transferred to a new vessel with fresh medium. The process will continue over five passages (approximately four to seven weeks).
Der spezifische Nachweis der Borrelien erfolgt durch Westernblot gemäß Beispiel 1.The specific detection of Borrelia is carried out by Western blotting according to Example 1.
Ergebnisse:Results:
Die Ergebnisse entsprechen im Wesentlichen Beispiel 1. Der wiederholte Transfer der Borrelien in frisches Medium führt zu erneutem exponentiellem Wachstum. Dabei spielt es keine Rolle, von welchem verbrauchten Medium (Zusammensetung gemäß Tabelle 1, Zusammensetung gemäß Tabelle 2, Complete BSK-H) in welches frische Medium (Zusammensetung gemäß Tabelle 1, Zusammensetung gemäß Tabelle 2, Complete BSK-H) überimpft wird. Neben der Zunahme der Organismenzahl in der Ausgangskultur ist dies ein weiterer Beweis der Lebensfähigkeit der Mehrheit der enthaltenen Bakterien.The results essentially correspond to Example 1. The repeated transfer of Borrelia into fresh medium leads to renewed exponential growth. It does not matter from which spent medium (composition according to Table 1, composition according to Table 2, Complete BSK-H) in which fresh medium (composition according to Table 1, composition according to Table 2, Complete BSK-H) is inoculated. In addition to the increase in the number of organisms in the starting culture, this is further evidence of the viability of the majority of the bacteria contained.
Claims (12)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE200610045252 DE102006045252B4 (en) | 2006-09-26 | 2006-09-26 | Protein-free medium for the cultivation of Borrelia and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE200610045252 DE102006045252B4 (en) | 2006-09-26 | 2006-09-26 | Protein-free medium for the cultivation of Borrelia and its use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE102006045252A1 DE102006045252A1 (en) | 2008-04-10 |
| DE102006045252A8 DE102006045252A8 (en) | 2008-07-17 |
| DE102006045252B4 true DE102006045252B4 (en) | 2012-12-27 |
Family
ID=39154455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE200610045252 Expired - Fee Related DE102006045252B4 (en) | 2006-09-26 | 2006-09-26 | Protein-free medium for the cultivation of Borrelia and its use |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE102006045252B4 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008057396A2 (en) | 2006-11-03 | 2008-05-15 | Schering-Plough Ltd. | Canine lyme disease vaccine |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001079451A1 (en) * | 2000-04-14 | 2001-10-25 | Gensys, Inc. | Methods and compositions for culturing spirochetes and treating spirochetal diseases |
-
2006
- 2006-09-26 DE DE200610045252 patent/DE102006045252B4/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001079451A1 (en) * | 2000-04-14 | 2001-10-25 | Gensys, Inc. | Methods and compositions for culturing spirochetes and treating spirochetal diseases |
Non-Patent Citations (2)
| Title |
|---|
| ALBAN, P.S. [u.a.]: Serum-starvation-induced changes in protein synthesis and morphology of Borrelia burgdorferi. Microbiology (2000) 146 (Pt 1) 119-27 * |
| BOYLAN, J.A. [u.a.]: Borrelia oxidative stress response regulator, BosR: A distinctive Zn-dependent transcriptional activator. PNAS (2003) 100 (20) 11684-11689 * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE102006045252A8 (en) | 2008-07-17 |
| DE102006045252A1 (en) | 2008-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68925971T2 (en) | CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS | |
| Fogg et al. | Algal cultures and phytoplankton ecology | |
| US10308909B2 (en) | Dried spore germinative compound mixtures | |
| DE60015595T2 (en) | DEVICE FOR STORING AND IMPROVING MICROORGANISMS | |
| DE69133589T2 (en) | Nutrient medium for CHO cells and adapted cells | |
| DE69231331T2 (en) | TECHNOLOGY FOR CONCENTRATING CULTURAL MEDIA | |
| Maeda | Influence of ionic conditions on cell differentiation and morphogenesis of the cellular slime molds | |
| Soldo et al. | The cultivation of symbiote‐free marine ciliates in axenic medium | |
| Gujjar et al. | The effect of estradiol on Candida albicans growth | |
| DE69836275T2 (en) | CELL CULTURE MEDIA FOR THE SPECIFIC DETECTION OF VARIOUS CANDIDA SPECIES, AS WELL AS TEST METHODS | |
| Li et al. | Specific growth rate, colonial morphology and extracellular polysaccharides (EPS) content of Scenedesmus obliquus grown under different levels of light limitation | |
| DE2723185A1 (en) | METHOD FOR DETERMINING MUTAGENESIS IN DIPLOID HUMAN LYMPHOBLASES | |
| DE60309862T2 (en) | plating | |
| DE3110559A1 (en) | "FULLY SYNTHETIC CELL CULTURE MEDIUM" | |
| DE102006045252B4 (en) | Protein-free medium for the cultivation of Borrelia and its use | |
| DE69737455T2 (en) | DEFINED SYSTEMS FOR CULTURING EPITHELIAL CELLS AND APPLYING THE SAME | |
| Chaleff | Induction, maintenance, and differentiation of rice callus cultures on ammonium as sole nitrogen source | |
| DE3711699C2 (en) | ||
| Mishek et al. | Development of a chemically-defined minimal medium for studies on growth and protein uptake of Gemmata obscuriglobus | |
| CN118370247B (en) | Method for improving survival rate of hong Kong giant oyster under high-salt condition | |
| D'Mello et al. | The action of sodium deoxycholate on Escherichia coli | |
| EP1516045B1 (en) | Use of glutamin-free medium | |
| US4687744A (en) | Artificial culture of the sexual stage of lagenidium giganteum | |
| CN111621470B (en) | High-efficiency low-toxicity myocardial purification culture medium and method | |
| RU2106879C1 (en) | Method for culturing slowly growing mycobacteria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8196 | Reprint of faulty title page (publication) german patentblatt: part 1a6 | ||
| OP8 | Request for examination as to paragraph 44 patent law | ||
| R081 | Change of applicant/patentee |
Owner name: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG, DE Free format text: FORMER OWNER: EUROIMMUN AG, 23560 LUEBECK, DE Effective date: 20120614 |
|
| R018 | Grant decision by examination section/examining division | ||
| R020 | Patent grant now final |
Effective date: 20130328 |
|
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |